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Release from Human Lung 
Fragments 
Abstract 
The actions of adenosine on histamine release of human lung fragments were 
investigated. Histamine release was stimulated either with the calcium iono-
phore A 23187 orwith concanavalin A. Adenosine and its analogue 5'-N-ethyl-
carboxamidoadenosine alone had no significant effect on basal release or on 
the release elicited by A 23187 or concanavalin A. However, in the presence of 
the adenosine receptor antagonist 8-[4-[[[[(2-aminoethyl)amino]-carbonyl] 
methyloxy]-phenyl]-1,3-dipropylaxanthine (XAC), which itself did not affect 
the release, adenosine increased the stimulated histamine release. On the 
other hand, in the presence of the nucleoside transport inhibitor S-(p-nitro-
benzyl)-6-thioninosine (NBTI), adenosine caused a reduction in stimulated 
histamine release. NBTI itself caused a stimulation of release. Thus, a stim-
ulatory effect of adenosine was seen in the presence ofXAC, whereas an inhib-
itory effect was unmasked by NBTI. From these data it is concluded that aden-
osine exerts two opposing effects on histamine release in the human lung wh ich 
neutralize each other: it inhibits release via a si te antagonized by XAC, which 
presumably represents an A2 adenosine receptor, and it stimulates release via a 
mechanism that is blocked by NBTI, suggesting that adenosine needs to reach 
the interior of cells to exert this effect. The slight stimulatory effect of NBTI 
alone demonstrates that trapping intracellularly formed adenosine inside mast 
cells leads to sufficient concentrations of adenosine to stimulate histamine re-
lease. These findings suggest an important bimodal role of adenosine in regu-
lating histamine release in the human lung. 
Adenosine appears to playa role in the pathophysiol-
ogy of bronchial asthma by modulating mast cell media tor 
secretion. There is also increasing evidence that during 
antigen provocation and hypoxia adenosine itself is re-
leased [1-3] and therefore should be considered as an ad-
ditional mediator of allergic reactions. 
Many of the actions of adenosine seem to be media ted 
by two types of cell surface receptors: the Al adenosine re-
ceptor which inhibits and the A2 adenosine receptor which 
activates adenylate cyclase. Millimolar concentrations of 
adenosine mayaiso act at an intracellular purine site with 
a resultant inhibition of adenylate cyclase [4,5]. In studies 
with human basophils, adenosine elevates cyclic AMP via 
an A2 adenosine receptor-mediated mechanism and in-
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hibits histamine release [~]. In contrast, adenosine po-
tentiates mediator secretion from rat peritoneal mast cells 
[9, 10]. Several laboratories have recently reported that 
this stimulation could not be antagonized by adenosine re-
ceptor antagonists, such as theophylline. Two different hy-
potheses have been put forward to interpret this finding: 
some authors postulate the existence of a novel type of cell 
surface adenosine receptor that is not blocked by methyl-
xanthines [11-13]. This proposal is supported by a mod-
ulation of the effects of adenosine by pertussis toxin and 
cholera toxin, known to affect G-protein function. Obser-
vations made in our laboratory, however, seem to argue 
against a cell surface action of adenosine to enhance 
mediator release. Because the nucleoside transport inhib-
itor S-(p-nitrobenzyl)-6-thioinosine (NBTI) abolished 
these effects of adenosine, we concluded that adenosine 
acts at an intracellular si te [10]. Stimulation of this site ap-
pears to result in an enhanced sensitivity of the release 
process to calcium and, hence, results in enhanced release 
of mediators. 
In addition to these effects on mast cell mediator re-
lease, adenosine and its analogue 5'-N-ethylcarboxami-
doadenosine (NECA) activate adenylate cyclase and ele-
vate intracellular cyclic AMP levels of intact rat peritoneal 
mast cells. This elevation of cyclic AMP levels is antag-
onized by theophylline and is thought to be media ted by 
A2 adenosine receptors. Hence, an action of adenosine at 
two distinct sites in mast cells has been assumed [10]. 
However, recent studies show that mast cells and ba-
sophils from different species and even from different 
sites in the same species may differ in structure and func-
tion [14, 15]. In particular, the effect of adenosine on hu-
man lung mast cells is still controversial. Potentiation 
[16--18] as well as inhibition [16, 17, 19-21] of mediator se-
cretion have been described. Methylxanthines antag-
onized both potentiation and inhibition in dispersed hu-
man lung mast cells [17], but antagonized only inhibition in 
human lung fragments [19]. The receptor subtype was 
identified as A2 by the rank order of potency of adenosine 
and its synthetic analogues [17,19]. However, recent stud-
ies suggested a distinct, unclassified adenosine receptor 
responsible for potentiation of histamine release [18, 22]. 
The present study was undertaken in order to see 
whether the dual control of mediator release from rat pe-
ritoneal mast cells - i.e. inhibition via A2 receptors and 
stimulation via a presumably intracellular site [10, 23] -
could also be detected in the human lung and could ex-
plain the contradictory effects described above. We chose 
to investigate this question using human lung fragments 
for three reasons: first we were interested in the net effect 
in the complex environment of the lung rather than in ef-
fects observable in isolated cell populations. Second, in 
contrast to isolated pulmonary mast cells, they contain the 
different mast cell subpopulation in their original compo-
sition, and third, lung fragments offer the advantage that 
cells are not altered by enzymatic treatment and long in-
cubation periods in the absence of calcium known to de-
crease reactivity to secretagogues [24]. Although mast 
cells constitute only 2% of the lung tissue, they contain 
most of the tissue histamine stored in cytoplasmatic gran-
ules [25]. Thus histamine release of lung fragments repre-
sents the function of lung mast cells. 
Materials and Methods 
Materials 
Adenosine was obtained from Boehringer, Mannheim, FRG, and 
concanavalin A from Serva, Heidelberg, FRG. The calcium iono-
phore A 23187, NBTI and histamine were purchased from Sigma, 
München, FRG. NECA was a gift from Byk Gulden, Konstanz, FRG, 
and the xanthine amine congener 8-[4-[[[[(2-aminoethyl)amino]-car-
bonyl]methyloxy]-phenyl] -1,3-dipropylxanthine (XAC) was donated 
by Dr. Entzeroth, Thomae, Biberach, FRG. All drugs were of analyt-
ical grade. 
Preparation 0/ Human Lung Tissue 
Spec-imens of macroscopically normal areas of peripheral human 
lung were obtained at the time of surgery for carcinoma of the bron-
chus and were immediately immersed in Hepes-buffered saline 
(4°C). Within 1 h, the tissue was transported on ice to the laboratory. 
All subsequent steps were carried out at 4 oe. The lung tissue was dis-
sected free of pleura, large bronchi and blood vessels and chopped 
into 1 x 0.2 x 0.2 mm fragments using a McIllwain tissue chopper. Tis-
sue fragments were then suspended in Hepes-buffered saline con-
taining 137 mM NaCI, 2.7 mM KCI, 0.4 mM NaH2P04, 10 mM Hepes, 
5.5 mM glucose and bovine serum albumine 0.05%, pH 7.4 (adjusted 
with NaOH before use) and were centrifuged for 5 min at 120 g. This 
washing step was repeated three times, and the tissue fragments re-
suspended in incubation buffer which was washing buffer comple-
mented with 1 mM CaCl2 and 0.5 mM MgCI2• 
Histamine Release Experiments 
The incubation was performed in duplicates at 37°C with gentle 
mechanical agitation. Controls were fragments incubated in buffer 
alone. Approximately 40 mg lung tissue (wet weight) was preincu-
bated for 10 min in 0.95 ml incubation buffer containing XAC or 
NBTI. NECA and adenosine were added 5 min before stimulation. 
Histamine release was stimulated by adding 50 f.LI incubation buffer 
with either calcium ionophore A 23187 (1 ~ final concentration un-
less indicated otherwise) or concanavalin A (1 mg/mI). The histamine 
release was terminated by chilling the sampies to 4°C and centrifu-
gation at 300 g for 10 min. 
Extraction and Fluorometric Assay 0/ Histamine 
For extractions of histamine from supernatant and pellet and the 
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Fig. 1. Effect of the calcium ionophore A 23187 on histamine re-
lease from human lung fragments at 90 min of incubation. Values are 
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Fig. 2. Time course of the calcium ionophore A 23187-induced 
histamine release. Experiments were performed with 2 and 3.5 ~ fi-
nal concentrations of the calcium ionophore or without stimulation 
(basal release). Values are means ± SEM of four separate experi-
ments with duplicate sampIes. 
from the tissue pellet and the supernatant was removed by perchloric 
acid precipitation. Histamine was then extracted into n-butanol from 
the alkalinized salt-saturated sampIe. The histamine was recovered 
in an aqueous solution of 0.1 N HCI by adding heptane. This solution 
was then used for the condensation of histamine with opthalaldehyde 
modified by the citric acid stop [27] and the condensation reaction at 
o °C [28]. Histamine release was expressed as a percentage of the to-
tal histamine content (tissue plus medium). The experiments were re-
peated 4-5 times, and for every separate experiment a tissue prep-
aration of an individual patient was used. The total histamine content 
of the human lung tissue ranged from 7 to 25 ~g!g lung tissue (9.8 ± 
0.1 g me an ± SEM, n = 79) and thus was in good agreement with re-
sults obtained in other studies [27, 29, 30]. 
Statistics 
Statistical significances of nucleoside-related effects were ana-
lyzed by comparing control and nucleoside-treated tissue fragments 
using Student's t test for paired data. Values were considered signif-
icant at p < 0.05. 
Results 
Stimulation of Histamine Release by A 23187 and 
Concanavalin A 
Human lung fragments incubated for 90 min with the 
calcium ionophore A 23187 showed a concentration-de-
pendent increase in histamine release with an ECso value 
of 1.7 ~. Maximal stimulation occurred at a concentra-
tion of 30 ~, which induced a histamine release of 
46.4 ± 1.4% (mean ± SEM) of total tissue content (fig.1). 
In all experiments, spontaneous histamine secretion was 
less than 10% during 90 min of incubation and maximally 
12.4% at 120 min. 
The rate of histamine release from human lung frag-
ments depended on the degree of stimulation. The time 
for histamine release to reach 50% of its eventual maxi-
mum (t1/2) was approximately 45 min at a concentration of 
2 ~ A 23187 and the release was complete by 120 min. 
With 3.5 ~ of the calcium ionophore, t1/2 was 30 min, and 
maximal histamine secretion was reached at 90 min 
(fig.2). 
Concanavalin A also induced a time- and dose-depen-
dent release of histamine. Compared with the stimulation 
by the calcium ionophore, the release was more rapid, but 
the maximal release was less. The highest concentration 
used was 1 mg/mI concanavalin A resulting in a histamine 
release (mean ± SEM) of15 ± 0.8% oftotal histamilJ.e con-
te nt at 30 min of incubation with a spontaneous release of 
7.5 ± 0.1 % (mean ± SEM, P < 0.05). Tl/2 was approximately 
8 min (fig. 3). 
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Effects 0/ Adenosine and NECA on Calcium 
Ionophore-Induced Histamine Release 
Approximately 30% of maximal histamine release was 
achieved by stimulation of human lung fragments with 
1 ~ calcium ionophore. Adenosine and its analogue 
NECA had no effect on basal (6.4±1.2% without, 
7.2 ± 1.3% with 100 11M adenosine and 6.6 ± 1.3% with 10 
~ NECA, me an ± SEM of three independent experi-
ments after a 90-min incubation period) or A 23187-in-
duced histamine release (fig. 4, 5). To determine wh ether 
extracellular adenosine receptors are involved, the adeno-
sine receptor antagonist XAC was used [31]. XAC (1 11M), 
which is one of the most effective A2-antagonists at the 
moment, had no influence on basal histamine release 
(6.4±1.2% without and 6.6±1.1% with XAC, me an 
± SEM of three independent experiments after 90 min of 
incubation) or on release stimulated by A 23187 (fig.4). 
However, in the presence of XAC, 100 11M adenosine sig-
nificantly enhanced stimulated histamine release (fig.4). 
The stimulation-evoked release was enhanced by almost 
40%. A similar enhancement was observed with 10 11M of 
the metabolically stable adenosine analogue NE CA 
(fig. 5). The nucleoside transport inhibitor NBTI (1 11M) 
had no effect on histamine release in unstimulated human 
lung fragments (basal histamine release: 6.4 ± 1.2%, with 
NBTI: 7.2 ± 1.5%, mean ± SEM of three independent ex-
periments after 90 min of incubation). However, in the 
presence of 1 11M NBTI, the calcium ionophore-induced 
histamine release was significantly enhanced (fig.4). In 
the presence of1 I1MNBTI, adenosine inhibited histamine 
release, whereas adenosine alone had no influence on his-
tamine release (fig. 4). The experiments involving NBTI 
were not done with NE CA, because NECA can diffuse 
across the cell membrane so that blockade of the nucleo-
side transporter would have little effect on its distribution. 
Effects 0/ Adenosine on Concanavalin A-Induced 
Histamine Release 
To confirm that adenosine not only modulates calcium 
ionophore-induced histamine release, we also challenged 
human lung fragments by bridging IgE molecules with 
concanavalin A (1 mg/mI). The findings were similar to 
those obtained with the calcium ionophore. Adenosine 
(100 11M) alone has no effect on the histamine release of 
activated human lung fragments (fig. 6). However, in the 
presence of XAC (1 11M), which had no effect on histamine 
release, adenosine potentiated the stimulated histamine 
release. In the presence of 1 11M NBTI, adenosine inhib-
ited histamine release (fig. 6). Stimulation and inhibition 
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Fig. 3. Time course of concanavalin A-induced histamine release. 
Experiments were performed with 0.01, 0.1 and 1 mg/mI final concen-
trations of concanavalin A or without stimulation (basal release). 





















Fig. 4. Effects of adenosine on calcium ionophore A 23187-in-
duced histamine release and its modulation by XAC and NBTI. The 
release was measured after stimulation with 1 J.iM calcium ionophore 
A 23187 and in the presence of 1 J.iM XAC or 1 J.iM NBTI. Human lung 
fragments were incubated for 90 min with and without (control) 100 
J.iM adenosine. The values show A 23187-induced histamine release 
corrected for basal histamine release, that was 7.5 ± 1.0% of total his-
tamine content (mean ± SEM). Statistically significant levels of po-
tentiation or inhibition compared to control (* p < 0.05) and com-
pared to A 23187-stimulated sampIes (** p < 0.05) are given. Values 
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Fig. 5. Effect of NECA on calcium ionophore A 23187-induced 
histamine release and its modulation by XAC. The release was mea-
sured after stimulation with 1 ~ calcium ionophore A 23187 and in 
the presence of 1 ~ XAC. Human lung fragments were incubated 
for 90 min with and without (control) 10 ~ NECA. The values show 
A 23187-induced histamine release corrected for basal histamine re-
lease, that was 9.2 ± 0.7% of total histamine content (me an ± SEM). 
Statistically significant levels of potentiation or inhibition compared 
to contra I (* p < 0.05) are given. Values are means ± SEM offive sep-
arate experiments with duplicate sampies. 
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Fig. 6. Effect of adenosine on concanavalin A-induced histamine 
release and its modulation by XAC and NBTI. The release was mea-
sured after stimulation with 1 mg/mI concanavalin A (con A) and in 
the presence of 1 ~ XAC or 1 ~ NBTI. Human lung fragments 
were incubated for 60 min with and without (control) 100 ~ adeno-
sine. The values show concanavalin A-induced histamine release cor-
rected for basal histamine release, that was 6.4 ± 1.1 % of total hista-
mine content (mean ± SEM). Statistically significant levels of poten-
tiation or inhibition compared to contral (* p < 0.05) and compared 
to concanavalin A-stimulated sampies (** p < 0.05) are given. Values 
are means ± SEM of four separate experiments with duplicate sam-
pIes. 
challenged with concanavalin A. A significant effect was 
already seen at 15 min of incubation (data not shown). 
Thus, adenosine was found to modulate histamine release 
from human lung tissue in a similar manner when release 
was stimulated by either A 23187 or concanavalin A. It in-
hibited release in the presence of NBTI and it stimulated 
release in the presence of XAC. 
Discussion 
Histamine release of human lung fragments was mod-
ulated by adenosine and its analogue NECA via two dif-
ferent mechanisms. NECA and adenosine alone did not 
influence media tor secretion activated by the calcium 
ionophore A 23187 or concanavalin A. In the presence of 
the adenosine receptor antagonist XAC, adenosine and 
NECA markedly increased calcium ionophore- and con-
canavalin A-induced histamine release. Because this po-
tentiation was observed after blockage of cell surface 
adenosine receptors, it is concluded that it is not mediated 
via a classical adenosine receptor. To determine the site of 
action where adenosine stimulates histamine release, the 
nucleoside transport inhibitor NBTI was used. The move-
me nt of nucleoside molecules across the plasma mem-
brane is a facilitated, bidirectional process mediated by 
specific nucleoside transporters [32]. Thus influx and ef-
flux of adenosine can be prevented by blockade of this 
transporter [32]. Abolishment of this transmembrane ex-
change by NBTI can increase intracellular adenosine con-
centrations, trapping intracellularly generated adenosine 
inside the cello Incubation of NBTI with activated human 
lung fragments enhanced histamine release, in agreement 
with the hypothesis [10, 23] that the stimulatory effect of 
adenosine is mediated by an intracellular mechanism. 
When NBTI blocked the transport of adenosine across the 
plasma membrane, extracellular exogenous adenosine in-
hibited the NBTI-induced histamine release. Under these 
conditions, exogenous adenosine could not enter the cell, 
suggesting that adenosine inhibits mediator secretion via a 
cell surface adenosine receptor. According to the kinetics 
of the histamine release, both effects of adenosine were 
more rapid after stimulation with concanavalin A com-
pared to the calcium ionophore. 
Since in human lung mast cells the adenosine receptor 
appears to be of the A2 subtype [17,19], which mediates a 
stimulation of adenylate cyclase, our results concur with 
studies that show an association of elevated cyclic AMP 
levels with inhibition of mediator release in human ba-
sophils and lung mast cells [33]. 
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Different ways of activating mast cells by concanavalin 
A or the calcium ionophore A 23187 [34] caused a similar 
enhancement in histamine release by adenosine. This sug-
gests that adenosine acts on a step beyond receptor activa-
tion. Prom our results, it cannot be exc1uded that adeno-
sine facilitated the transport of calcium into the cello How-
ever, studies with rat peritoneal mast cells [23, 35] showed 
an unchanged intracellular calcium concentration and 
suggested therefore as a mechanism an increase in the cal-
cium sensitivity of the release process. Concurring with 
these results in rat peritoneal mast cells [23], we found that 
trapping of adenosine inside the cell with the nuc1eoside 
transport inhibitor NBTI caused enhancement of hista-
mine release. Therefore, concentrations of endogenously 
generated adenosine seem to be sufficient to potentiate 
the release in human lung fragments. 
Adenosine, as an inflammatory mediator itself, is gen-
erated and possibly released after stimulation of mast cells 
[36]. Because of the bidirectional transport of nuc1eosides, 
high levels of adenosine in the extracellular space corre-
spond to elevated levels of intracellular adenosine [32]. 
Thus, adenosine appears to act through a positive feed-
back mechanism. By increasing the sensitivity of the re-
lease process to free intracellular calcium, a potentiation 
of mediator release is achieved [35]. 
Others have suggested that the enhancing effects of 
adenosine on mast cell mediator release might be caused 
by activation of an atypical adenosine receptor. To recon-
eile our data with this hypothesis, we would have to as-
sume that NBTI also acts as a full agonist at this receptor. 
While we cannot rule out this possibility, we feel that our 
interpretation is more likely to be true, beeause NBTI has 
been proved to be a very specific and potent nuc1eoside 
transport inhibitor in all tissues and cells tested. 
Ali et al. [13] recently reported the activation üf phos-
pholipase C in a rat tumor mast cell (RBL-2H3) byadeno-
sine and suggested that the resultant stimulation of pro-
tein kin ase C might be the basis of the enhaneement in 
mediator release. In accordance with our results, the au-
thors reported that methylxanthines did not block these 
effeets of adenosine. However, sinee the effects of adeno-
sine were abrogated by pertussis toxin as weIl as cholera 
toxin, it was assumed that adenosine acted on an atypical 
G-protein-coupled receptor. No experiments using aden-
osine uptake blockers were done, and thus further studies 
are necessary to establish the relationship between these 
data and ours. Clearly, effects mediated via intracellular G 
proteins would appear to be a possibility. 
In this study, human lung fragments were chosen to in-
vestigate the effects of adenosine on histamine release. 
Studies with mechanically and enzymatically dispersed 
mast cells have shown that human mast cells differ in their 
histamine conte nt as well as their releasability according 
to the isolation procedure [21, 37]. On the basis of his-
tochemical properties, density difference, histamine con-
tent and functional characteristics, van Overheld et al. [38] 
have characterized two different subtypes of human lung 
mast cells. This reflects the heterogeneity of mast cells 
within the lung tissue. Therefore, in human lung frag-
ments in contrast to dispersed mast cells, not only one sub-
population is investigated but the whole population of 
mast cells. 
The characteristics of histamine release in human lung 
fragments were similar to those in isolated human lung 
mast cells. Calcium ionophore and concanavalin A in-
duced a time- and dose-dependent histamine release. In 
agreement with previous reports [18,29, 39, 40], histamine 
release induced by the calcium ionophore was more pro-
nounced than that by concanavaliI) A reaching maximally 
46.4 and 15% of total histamine content, respectively. 
Compared to isolated human lung mast cells, histamine 
release in the lung fragments was slower. This is probably 
due to impaired penetration of the stimulating agent and 
delayed diffusion of the mediator. As in previous studies, 
histamine release induced by concanavalin A was more 
rapid than that caused by the calcium ionophore [29], and 
the rate of release depended upon the degree of stimula-
tion [16]. These results show that histamine release in tis-
sue fragments reflects the function of the lung mast cells. 
In summary, histamine release from human lung frag-
ments appears to be regulated by adenosine in a dual man-
ner: potentiation and inhibition of histamine release, re-
sulting overall in an unchanged mediator secretion. Con-
centrations of adenosine achieved by trapping endo-
genously generated adenosine inside the cell with the 
nuc1eoside transport inhibitor NBTI were sufficient to po-
tentiate histamine release. These data suggest that endo-
genous adenosine is capable to affect histamine release in 
the human lung. Since adenosine can either inhibit or 
stimulate histamine release, it appears to be a unique reg-
ulator of this process. 
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